Skip Navigation


JAC Advance Access originally published online on April 14, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/5/1099    most recent
dkg214v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Keller, M. J.
Right arrow Articles by Herold, B. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keller, M. J.
Right arrow Articles by Herold, B. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 1099-1102
© 2003 The British Society for Antimicrobial Chemotherapy

Leading Article

Rigorous pre-clinical evaluation of topical microbicides to prevent transmission of human immunodeficiency virus

Marla J. Keller1, Mary E. Klotman1 and Betsy C. Herold2,*

Departments of 1 Medicine and 2 Pediatrics, Division of Infectious Disease, Box 1657, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA

Keywords: HIV, microbicides

The first 150 words of the full text of this article appear below.

With over 40 million people world-wide living with human immunodeficiency virus (HIV) and an estimated 16 000 new infections each day,1 there is an urgent need to identify safe and effective topical microbicides. Microbicides are products designed to prevent acquisition or transmission of HIV and other sexually transmitted infections (STIs) when applied in the vagina or rectum. Microbicides offer the potential to dramatically reduce rates of transmission of STIs, including HIV. Mathematical modelling predicts that over 3 years, 2.5 million infections could be averted if a microbicide that is 60% effective against HIV were used by 20% of women in half of all sex acts that do not involve a condom.2

More than 50 topical microbicides are in development. Some will be contraceptive and all will be controlled by the user. Fourteen of the leading compounds have advanced from pre-clinical testing (cell culture and animal studies) to Phase I/II human clinical . . . [Full Text of this Article]


   Acknowledgements
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
K. C. Yim, C. J. Carroll, A. Tuyama, N. Cheshenko, M. J. Carlucci, D. D. Porter, G. A. Prince, and B. C. Herold
The Cotton Rat Provides a Novel Model To Study Genital Herpes Infection and To Evaluate Preventive Strategies
J. Virol., December 1, 2005; 79(23): 14632 - 14639.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Cheshenko, W. Liu, L. M. Satlin, and B. C. Herold
Focal Adhesion Kinase Plays a Pivotal Role in Herpes Simplex Virus Entry
J. Biol. Chem., September 2, 2005; 280(35): 31116 - 31125.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
N. Bourne, R. Stegall, R. Montano, M. Meador, L. R. Stanberry, and G. N. Milligan
Efficacy and Toxicity of Zinc Salts as Candidate Topical Microbicides against Vaginal Herpes Simplex Virus Type 2 Infection
Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1181 - 1183.
[Abstract] [Full Text] [PDF]